Collaboration for Success: Multi-Regional Clinical Development
May 25, 2018
12:30 PM - 4:00 PM
Yale Club Manhattan
12:30-1:00 PM Network Reception and Lunch
1:00-1:10 PM Opening Statement
DoHyun Cho, PhD
Chairman, New York Health Forum
1:10-2:10 PM Session 1
“Current CRO M&A and Investment Trends"
The 1st session, “Current CRO M&A and Investment Trends” is designed to provide insights on “What would be the major trend and outlook for global CRO industry”. The CRO industry has seen a large number of mergers and acquisitions (M&A) over the past five years with key industry players becoming giants with more comprehensive coverage in terms of geography and specialties. These growing activities can be the result of several factors. In this session, we discuss the current trend and landscape of the CRO industry in various aspects, including rising global competition perspective.
Kimberly Ha (Founder, KKH Advisors) (Moderator)
Vincent Liu, PhD (Senior Advisor, Fosun Pharma)
David Blume (Managing Director, Edgemont Capital Partners)
John Bradley, MD (Managing Director, Torreya Partners)
2:10-2:30 PM Networking Break
2:30-3:10 PM Session 2
“Key Considerations for Successful Multi-Regional Clinical Trials”
The 2nd session, “Key Considerations for successful Multi-Regional Clinical Trials” is designed to provide insights on significant growth of multi-regional clinical trials and ever-more increasing sponsor demands for successful study results in multi-national atmosphere. In this session, we discuss the current trends and landscapes of the CRO industry in the global setting and the requirements for a successful global development.
Joe McMenamin, MD, JD (EVP, W Medical Strategy Group) (Moderator)
Jeff Clark, MD, JD (Chief Licensing Officer, Enzychem Lifesciences)
Eunie Kim (Advisor, C&R Research)
John Choi, MS (Project Director, Enzychem Lifesciences)
3:10-3:50 PM Session 3
“Quality and Tech in Clinical Development"
The 3rd session, “Quality and Tech in Clinical Development” is designed to provide insights on art-of-the state technologies and methodologies associated with clinical development and human quality of life. In this session, we share expert views on technology assessments and disruptive technology related to machine learning and artificial intelligence in the clinical trials as well as the trending diagnostics tools to overcome unmet medical needs.
Surani Fernando (Editor, North America, Biopharm Insight) (Moderator)
Scott Howell, MD, MPH&TM, CPE (Chief Medical Officer, Tenet Diagnostics)
Anthony Chambers (Director, Life Sciences Practice, West Monroe Partners)
3:50-4:00 PM Closing & Networking